TuHURA Biosciences completes acquisition of Kineta; Kineta stockholders get 0.185298 HURA shares each

KINETA, INC./DE

• Each Kineta share converted into 0.185298 shares of TuHURA common stock; ~2.87M HURA shares issued at close.
• 2nd contingent consideration: 1,129,885 additional HURA shares issuable after 6 months, subject to loss adjustments.
• Kineta VISTA mAb (KVA12123, now TBS-2025) added; Phase 2 trial in NPM1-mutated AML planned for H2 2025.
• Fourth tranche of $12.5M PIPE financing unlocked upon closing.
• Kineta stock halted on OTC Pink; company will file Form 15 to terminate SEC registration. All directors/officers resigned.